| Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry L Branstetter, C Chatterjee, MJ Higgins The RAND Journal of Economics 47 (4), 857-890, 2016 | 91 | 2016 |
| Does environmental regulation indirectly induce upstream innovation? New evidence from India P Chakraborty, C Chatterjee Research Policy 46 (5), 939-955, 2017 | 60 | 2017 |
| Strong medicine: Patent reform and the emergence of a research-driven pharmaceutical industry in India A Arora, L Branstetter, C Chatterjee NBER Conference on Location of Biopharmaceutical Activity, Boston, MA, 7-8, 2008 | 40 | 2008 |
| Ethical issues in health care sector in India C Chatterjee, V Srinivasan IIMB Management Review 25 (1), 49-62, 2013 | 33 | 2013 |
| Starving (or fattening) the golden goose?: generic entry and the incentives for early-stage pharmaceutical innovation L Branstetter, C Chatterjee, MJ Higgins National Bureau of Economic Research, 2014 | 32 | 2014 |
| The consumer welfare implications of governmental policies and firm strategy in markets for medicines C Chatterjee, K Kubo, V Pingali Journal of Health Economics 44, 255-273, 2015 | 19 | 2015 |
| Gender and its rising role in modern Indian innovation and entrepreneurship C Chatterjee, S Ramu IIMB Management Review 30 (1), 62-72, 2018 | 18 | 2018 |
| Mitigating regulatory impact: the case of partial price controls on metformin in India A Bhaskarabhatla, C Chatterjee, P Anurag, E Pennings Health policy and planning 32 (2), 194-204, 2017 | 15 | 2017 |
| Hit where it hurts: cartel policing using targeted sales and supply embargoes A Bhaskarabhatla, C Chatterjee, B Karreman The Journal of Law and Economics 59 (4), 805-846, 2016 | 15 | 2016 |
| Strong medicine? Patent reform and the transformation of the Indian pharmaceutical industry A Arora, L Branstetter, C Chatterjee, K Saggi mimeo, 2009 | 15 | 2009 |
| Price Control and Access to Drugs: The Case of India’s Malaria Market D Mohapatra, C Chatterjee Working Paper. Cornell University, 2015 | 14 | 2015 |
| Innovation and internationalisation in the Indian software industry: Wipro–Going forward: Interview with Rishad Premji, Chief Strategy Officer, Wipro Limited C Chatterjee IIMB management Review 26 (1), 59-64, 2014 | 11 | 2014 |
| The role of physicians in prescribing irrational fixed-dose combination medicines in India A Bhaskarabhatla, C Chatterjee Social science & medicine 174, 179-187, 2017 | 10 | 2017 |
| Government health insurance and spatial peer effects: New evidence from India C Chatterjee, R Joshi, N Sood, P Boregowda Social Science & Medicine 196, 131-141, 2018 | 7 | 2018 |
| Fundamental Patent Reform and the Private Returns to R&D The Case of Indian Pharmaceuticals C Chatterjee | 6 | 2007 |
| Women’s Disempowerment and Preference for Risky Skin Whitening Products: Experimental Evidence from India A Adbi, C Chatterjee, Z Kinias, J Singh INSEAD Working Paper, 2019 | 5* | 2019 |
| When the Big One Came: A Natural Experiment on Demand Shock and Market Structure in India's Influenza Vaccine Markets A Adbi, C Chatterjee, M Drev, A Mishra Production and Operations Management 28 (4), 810-832, 2019 | 4 | 2019 |
| First-mover advantages before and after TRIPS: Evidence from the Indian pharmaceutical industry A Bhaskarabhatla, C Chatterjee Available at SSRN 2154510, 2012 | 4 | 2012 |
| Did India's price control policy for coronary stents create unintended consequences? S Deo, H Tyagi, C Chatterjee, H Molakapuri Social Science & Medicine 246, 112737, 2020 | 3 | 2020 |
| Moving beyond the valley of death: regulation and venture capital investments in early-stage biopharmaceutical firms Y Kim, C Chatterjee, MJ Higgins National Bureau of Economic Research, 2018 | 3 | 2018 |
Lee BranstetterProfessor of Public Policy and Economics, Carnegie Mellon UniversityVerified email at cmu.edu
